Expression of the Hippo Pathway Core Components in Endometrial Cancer and Its Association with Clinicopathologic Features
- PMID: 36552980
- PMCID: PMC9776728
- DOI: 10.3390/diagnostics12122973
Expression of the Hippo Pathway Core Components in Endometrial Cancer and Its Association with Clinicopathologic Features
Abstract
Background: The Hippo signaling pathway has a key role in tumorigenesis. This study aimed to evaluate the relationship between the expression of core components of the Hippo signaling pathway and its association with clinicopathological features in endometrial cancer.
Materials and methods: We retrospectively collected endometrioid endometrial cancer specimens from 60 patients between January 2002 and December 2009 at Gyeongsang National University Hospital. Relevant clinicopathological data were obtained through electronic medical records of patients. The expression patterns of six core components (YAP, p-YAP, LATS1/2, MST1/2, KIBRA, and Merlin) were identified by immunohistochemistry on tissue microarray sections.
Results: The positive expression ratio was 75.0% for YAP, 73.3% for p-YAP, 26.7% for MST1/2, 16.7% for KIBRA, 15.0% for Merlin, and 15.0% for LATS1/2. YAP expression was negatively correlated with MST 1/2 kinases (p = 0.045) and positively correlated with p-YAP (p = 0.012). Merlin, and MST 1/2 kinases (p = 0.043) showed a positive correlation. A subgroup of patients aged below 60 years (p = 0.004) and with myometrial invasion depth of less than 1/2 (p = 0.041) showed a positive association with YAP expression. p-YAP expression was negatively associated with a subset of patients with primary tumour size ≥4 cm (p = 0.03). Logistic regression analysis showed a significant association between age and YAP expression. The odds ratio of p-YAP expression was significantly lower in the group with tumour size ≥4 cm.
Conclusion: Two prognostic factors, age and tumour size, were significantly associated with the expression of YAP and p-YAP in endometrial cancer. Further research should focus on their expression as a marker for prediction of clinicopathological implications in endometrial cancer.
Keywords: Hippo pathway; KIBRA; LATS1/2; MST1/2; YAP; endometrial cancer; p-YAP; prognostic factors.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Lipid kinase PIP5Kα contributes to Hippo pathway activation via interaction with Merlin and by mediating plasma membrane targeting of LATS1.Cell Commun Signal. 2023 Jun 19;21(1):149. doi: 10.1186/s12964-023-01161-w. Cell Commun Signal. 2023. PMID: 37337213 Free PMC article.
-
MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.Nat Commun. 2015 Oct 5;6:8357. doi: 10.1038/ncomms9357. Nat Commun. 2015. PMID: 26437443 Free PMC article.
-
WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy.Mol Cell. 2022 May 19;82(10):1850-1864.e7. doi: 10.1016/j.molcel.2022.03.027. Epub 2022 Apr 15. Mol Cell. 2022. PMID: 35429439
-
The Hippo pathway in disease and therapy: cancer and beyond.Clin Transl Med. 2014 Jul 10;3:22. doi: 10.1186/2001-1326-3-22. eCollection 2014. Clin Transl Med. 2014. PMID: 25097725 Free PMC article. Review.
-
The regulation and function of YAP transcription co-activator.Acta Biochim Biophys Sin (Shanghai). 2015 Jan;47(1):16-28. doi: 10.1093/abbs/gmu110. Epub 2014 Dec 8. Acta Biochim Biophys Sin (Shanghai). 2015. PMID: 25487920 Review.
Cited by
-
YAP/TAZ-associated cell signaling - at the crossroads of cancer and neurodevelopmental disorders.Front Cell Dev Biol. 2025 Jan 28;13:1522705. doi: 10.3389/fcell.2025.1522705. eCollection 2025. Front Cell Dev Biol. 2025. PMID: 39936032 Free PMC article. Review.
References
-
- Kong A., Johnson N., Kitchener H.C., Lawrie T.A. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst. Rev. 2012;18:CD003916. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous